截至12月31日，利德曼股东户数3.11万，较上期减少3.62%；人均流通股17487股，较上期增加3.76%。 2025年1月-9月，利德曼实现营业收入2.52亿元，同比减少10.49%；归母净利润-713.48万元，同比减少 765.83%。 分红方面，利德曼A股上市后累计派现1.43亿元。近三年，累计派现544.01万元。 1月7日，利德曼盘中下跌2.08%，截至13:44，报7.05元/股，成交5585.48万元，换手率1.44%，总市值 38.35亿元。 资金流向方面，主力资金净流出585.20万元，特大单买入0.00元，占比0.00%，卖出117.76万元，占比 2.11%；大单买入861.43万元，占比15.42%，卖出1328.87万元，占比23.79%。 利德曼今年以来股价涨1.15%，近5个交易日涨1.00%，近20日跌4.21%，近60日跌6.37%。 资料显示，北京利德曼生化股份有限公司位于北京市北京经济技术开发区兴海路5号，成立日期1997年 11月5日，上市日期2012年2月16日，公司主营业务涉及体外诊断试剂(生化、免疫、分子)、诊断仪器、 生物化学原料。主营业务收入构成为：体外 ...

Core Viewpoint - The stock of Weigao Blood Purification experienced a decline of 2.00% on January 7, 2025, with a trading price of 41.14 yuan per share and a market capitalization of 17.186 billion yuan. The company has shown a year-to-date stock price increase of 3.81% and a recent five-day increase of 2.49% [1]. Group 1: Financial Performance - For the period from January to September 2025, Weigao Blood Purification achieved a revenue of 2.736 billion yuan, representing a year-on-year growth of 3.45%. The net profit attributable to shareholders was 341 million yuan, reflecting a year-on-year increase of 7.92% [2]. - The company has distributed a total of 65.8213 million yuan in dividends since its A-share listing [3]. Group 2: Stock and Market Activity - As of January 7, 2025, the stock's trading volume was 76.4939 million yuan, with a turnover rate of 4.70%. The net outflow of main funds was 5.7063 million yuan, with large orders accounting for 16.12% of purchases and 23.57% of sales [1]. - The number of shareholders decreased by 20.95% to 24,800, while the average circulating shares per person increased by 26.51% to 1,535 shares [2]. Group 3: Company Overview - Weigao Blood Purification, established on December 27, 2004, is located in Weihai, Shandong Province. The company specializes in the research, production, and sales of blood purification medical products. Its revenue composition includes consumables (77.55%), equipment (18.25%), and other categories (4.20%) [1].

1月7日，利欧股份盘中下跌2.11%，截至10:22，报6.49元/股，成交58.93亿元，换手率15.28%，总市值 439.49亿元。 资金流向方面，主力资金净流出3.20亿元，特大单买入7.19亿元，占比12.20%，卖出9.56亿元，占比 16.22%；大单买入10.87亿元，占比18.45%，卖出11.70亿元，占比19.86%。 截至9月30日，利欧股份股东户数68.18万，较上期增加34.00%；人均流通股8580股，较上期减少 25.37%。2025年1月-9月，利欧股份实现营业收入144.54亿元，同比减少8.80%；归母净利润5.89亿元， 同比增长469.10%。 分红方面，利欧股份A股上市后累计派现7.98亿元。近三年，累计派现4.27亿元。 机构持仓方面，截止2025年9月30日，利欧股份十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股6080.40万股，相比上期增加324.80万股。广发中证传媒ETF联接A（004752）位居第六大 流通股东，持股2480.00万股，相比上期减少131.30万股。 责任编辑：小浪快报 利欧股份今年以来股价涨15.07%，近5个交易日涨 ...

1月7日，万邦德盘中下跌2.07%，截至10:21，报13.74元/股，成交6541.53万元，换手率0.85%，总市值 84.05亿元。 资金流向方面，主力资金净流出862.65万元，特大单买入217.10万元，占比3.32%，卖出918.92万元，占 比14.05%；大单买入1380.43万元，占比21.10%，卖出1541.26万元，占比23.56%。 万邦德今年以来股价跌1.36%，近5个交易日涨0.88%，近20日涨10.18%，近60日跌4.58%。 资料显示，万邦德医药控股集团股份有限公司位于浙江省台州市温岭市城东街道百丈北路28号，成立日 期1999年3月31日，上市日期2006年11月20日，公司主营业务涉及铝加工产品、医疗器械产品的生产与 销售;现代中药、化学原料药及化学制剂的研发、生产和销售业务。主营业务收入构成为：医疗器械 41.63%，化学原料药及制剂24.69%，其他商品19.61%，中药14.07%。 万邦德所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：小盘、医疗器械、一带一路、 有色铝、增持回购等。 截至9月30日，万邦德股东户数2.64万，较上期减少32.75% ...

商报讯(记者叶晓珺)进入2026年，IPO市场热潮延续。1月5日，北交所上市委员会召开2026年第1次审议 会议，作为今年首家上会的IPO企业，舟山晨光电机股份有限公司(以下简称"晨光电机")顺利通过审 议，拉开北交所全年IPO序幕。据悉，晨光电机于2025年6月25日申报北交所公开发行，保荐机构为国 金证券。公司已深耕微特电机研发生产领域二十余年，产品主要应用于以吸尘器为主的清洁电器领域。 本次IPO拟募集3.99亿元，用于高速电机、控制系统及电池包扩能建设项目，研发中心建设项目。作为 国家级专精特新"小巨人"企业，其客户涵盖石头科技、追觅科技、LG、飞利浦、松下、德尔玛 （301332）、小米、美的等国内外知名品牌。 浙江"小巨人"晨光电机顺利过会 据招股书披露，晨光电机是专业从事微特电机研发、生产和销售的国家级高新技术企业、国家级专精特 新"小巨人"企业、浙江省"隐形冠军"企业、浙江省制造业单项冠军培育企业，可提供适用于多种应用场 景的全系列微特电机产品，主要包括交流串激电机、直流无刷电机、直流有刷电机三大品类。 据介绍，高速电机等扩能项目位于浙江省舟山市岱山经济开发区，项目占地约51.19亩，项目建成 ...

Group 1 - The core viewpoint of the news is that Baiyang Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.02% and a current price of 24.72 yuan per share, resulting in a market capitalization of 12.993 billion yuan [1] - Baiyang Pharmaceutical's main business involves providing comprehensive commercialization solutions for pharmaceutical product manufacturers, including brand operation, wholesale distribution, and retail, with brand operation accounting for 72.41% of total revenue [1] - The company has seen a year-to-date stock price increase of 4.75%, with a 3.30% rise over the last five trading days and a 9.14% increase over the last 20 days, while experiencing a 6.89% decline over the last 60 days [1] Group 2 - As of September 30, the number of shareholders for Baiyang Pharmaceutical is 11,100, a decrease of 40.83% from the previous period, while the average circulating shares per person increased by 68.99% to 47,194 shares [2] - For the period from January to September 2025, Baiyang Pharmaceutical reported a revenue of 5.627 billion yuan, a year-on-year decrease of 8.41%, and a net profit attributable to shareholders of 476 million yuan, down 25.67% year-on-year [2] - Since its A-share listing, Baiyang Pharmaceutical has distributed a total of 1.551 billion yuan in dividends, with 1.201 billion yuan distributed over the past three years [3]

Group 1 - The core viewpoint of the news is that the stock price of Chongqing Shanwaishan Blood Purification Technology Co., Ltd. has shown fluctuations, with a recent decline of 2.01% and a current trading price of 15.61 yuan per share, while the company has experienced a year-to-date stock price increase of 4.28% [1][2] - As of October 31, 2025, the company reported a revenue of 584 million yuan, representing a year-on-year growth of 39.79%, and a net profit attributable to shareholders of 104 million yuan, reflecting a year-on-year increase of 68.68% [2] - The company specializes in the research, production, and sales of blood purification equipment, with its main business revenue composition being 66.12% from blood purification equipment, 23.89% from blood purification consumables, 8.31% from medical services, and 1.68% from other sources [2] Group 2 - The company has distributed a total of 104 million yuan in dividends since its A-share listing [3] - As of September 30, 2025, the top ten circulating shareholders include new shareholder Penghua Medical Technology Stock A, holding 5.182 million shares, and BoShi Medical Care Mixed A, holding 3.257 million shares, with the latter's shareholding remaining unchanged from the previous period [3]

Core Viewpoint - Furuimei Medical experienced a stock price decline of 2.02% on January 6, 2025, with a trading volume of 331 million yuan and a total market capitalization of 19.065 billion yuan [1] Group 1: Stock Performance - As of January 6, 2025, Furuimei Medical's stock price was 71.95 yuan per share, with a year-to-date increase of 2.19% [1] - Over the last five trading days, the stock has decreased by 4.17%, while it has increased by 2.42% over the last 20 days and 4.52% over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Furuimei Medical reported a revenue of 1.101 billion yuan, representing a year-on-year growth of 12.37% [2] - The net profit attributable to shareholders for the same period was 112 million yuan, reflecting a year-on-year increase of 9.69% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Furuimei Medical was 26,700, an increase of 3.24% from the previous period [2] - The average number of circulating shares per shareholder was 8,742, which decreased by 3.09% compared to the previous period [2] Group 4: Dividend and Institutional Holdings - Furuimei Medical has distributed a total of 246 million yuan in dividends since its A-share listing, with 52.61 million yuan distributed over the last three years [3] - As of September 30, 2025, major institutional shareholders included Huabao Zhongzheng Medical ETF and Ruiyuan Growth Value Mixed A, with notable changes in their holdings [3]

Core Viewpoint - Yirui Technology's stock has shown a positive trend with a year-to-date increase of 8.66% and a recent uptick of 2.02% on January 6, 2025, indicating strong market interest and performance in the medical device sector [1]. Group 1: Stock Performance - As of January 6, 2025, Yirui Technology's stock price reached 109.87 yuan per share, with a trading volume of 2.24 billion yuan and a turnover rate of 1.03%, resulting in a total market capitalization of 23.232 billion yuan [1]. - The stock has experienced a 6.67% increase over the last five trading days and an 8.41% increase over the last 20 trading days, while it has seen a decline of 5.01% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Yirui Technology reported a revenue of 1.549 billion yuan, reflecting a year-on-year growth of 14.22%, and a net profit attributable to shareholders of 471 million yuan, which is a 20.61% increase compared to the previous year [2]. - The company has distributed a total of 789 million yuan in dividends since its A-share listing, with 557 million yuan distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Yirui Technology increased to 8,011, marking a 14.61% rise, while the average number of circulating shares per person decreased by 12.74% to 24,992 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is a new entrant holding 3.802 million shares, while Huabao Zhongzheng Medical ETF has exited the list [3]. Group 4: Business Overview - Yirui Technology, established on March 7, 2011, and listed on September 18, 2020, specializes in the research, production, sales, and service of digital X-ray detectors, with the main revenue sources being detector sales (81.21%), core component sales (7.66%), solution/technical service income (5.89%), accessory sales (4.57%), and rental income (0.66%) [1]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device sector, and is associated with various concepts including medical devices, mid-cap stocks, margin financing, security, and share buybacks [1].

3、根据2024年年报，公司海外营收占比为90.61%，受益于人民币贬值。 来源：新浪证券-红岸工作室 1月5日，采纳股份涨11.05%，成交额1.61亿元，换手率7.53%，总市值35.38亿元。 异动分析 辅助生殖+医疗器械概念+人民币贬值受益 1、公司采纳医疗于2018年开始向Thermo Fisher 供应试管婴儿培育管产品。 2、公司主营业务为从事注射穿刺器械及实验室耗材的研发、生产和销售。公司目前主要产品为穿刺 针、注射器、实验室耗材及口罩等。 该股筹码平均交易成本为27.80元，近期该股有吸筹现象，但吸筹力度不强；目前股价靠近压力位 29.73，谨防压力位处回调，若突破压力位则可能会开启一波上涨行情。 公司简介 资料显示，采纳科技股份有限公司位于江苏省江阴市华士镇澄鹿路253号，成立日期2004年7月23日，上 市日期2022年1月26日，公司主营业务涉及医用和兽用注射穿刺器械及实验室耗材的研发、生产和销 售。主营业务收入构成为：注射器45.17%，穿刺针45.01%，实验室耗材5.49%，其他4.33%。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分 ...